Conference call today at 8:30 am ETVANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a...
Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,...
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused...
FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical...
Revolutionary "Neuro-Skeletal Geometry" Methodology Promises a Drug-Free, Painless Approach to Treating a Range of Psychological and Physical AilmentsDALLAS, TX /...
REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of...
JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the...
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which...
LA JOLLA, Calif., Nov. 19, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
The 10-year strategic collaboration builds on strong research foundations in medical imaging and expands the scope to advance the delivery...
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing...
TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for...
Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene...
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target...
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease –...
This corrects and replaces the release that was disseminated earlier todayLack of OHE-specific diagnostic code in hospitals may increase risk...
Lack of OHE-specific diagnostic code in hospitals may increase risk of additional cost, length of hospitalization and additional burdens for...
Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and...
-- Blocking of α5β1 integrin has been shown to improve motor function and increase survival in the SOD1G93A mouse model of...
Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal...